


AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound of ~~having~~ the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein R₁ is hydrogen, aliphatic, heteroaliphatic, alicyclic, ~~heteroalicyclic, or aryl or heteroaryl~~;

R₂ and R₃ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, or an aliphatic, heteroaliphatic, alicyclic, ~~heteroalicyclic, or aryl or heteroaryl~~ moiety; or

R₁ and R₂, when taken together, may form a substituted or unsubstituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;

or R₁ and R₃, when taken together, may form a substituted or unsubstituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;

R₄ is hydrogen or halogen;

R₅ is hydrogen, ~~or an oxygen protecting group or a prodrug moiety~~;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R₇, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or an aliphatic moiety optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R₉ is ~~hydrogen, halogen, hydroxyl, protected hydroxyl, OR₁₂, SR₁₂, or NR₁₂R₁₃~~;

~~-X₁(CH₂)_p-X₂-R₁₄, or is C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or -X₁(CH₂)_p-X₂-R₁₄;~~

wherein R₁₂ and R₁₃ are, independently for each occurrence, hydrogen, aliphatic, heteroaliphatic, alicyclic, ~~heteroalicyclic, or aryl or heteroaryl~~; or a protecting group, ~~or -R₁₂ and -R₁₃, taken together may form a saturated or unsaturated cyclic ring~~

containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms; and each of R₁₂ and R₁₃ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,

wherein X₁ and X₂ are each independently absent, or are oxygen, NH, or -N(alkyl), or wherein X₂-R₁₄ together are N₃ or are a saturated or unsaturated heterocyclic moiety;

p is 2-10, and

R₁₄ is hydrogen, or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is -(C=O)NHR₁₅, -(C=O)OR₁₅, or -(C=O)R₁₅, wherein each occurrence of R₁₅ is independently hydrogen, aliphatic, heteroaliphatic, alicyclic, heteroalicyclic, aryl or heteroaryl; or R₁₄ is -SO₂(R₁₆), wherein R₁₆ is an aliphatic moiety, wherein one or more of R₁₄, R₁₅, or R₁₆ are optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen; or

R₈ and R₉ may, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;

R₁₀ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;

R₁₁ is hydrogen, hydroxyl or protected hydroxyl;


X is absent or is O, NH, N-alkyl, CH₂ or S;

Y is CHR₁₇, O, C=O, CR₁₇ or NR₁₇; and Z is CHR₁₈, O, C=O, CR₁₈ or NR₁₈, wherein each occurrence of R₁₇ and R₁₈ is independently hydrogen or aliphatic, or R₁₇ and R₁₈ taken together is -O-, -CH₂- or -NR₁₉-, wherein R₁₉ is hydrogen or C₁₋₆alkyl, and Y and Z may be connected by a single or double bond;

with the proviso that when n is 1; X is O; R₁ is methyl; R₂, R₃, R₄ and R₁₁ are each hydrogen; R₅ is hydrogen, C₁₋₄alkyl or -C(=O)C₁₋₄alkyl; R₆ is hydrogen, OH, C₁₋₄alkoxy or -OC(=O)C₁₋₄alkyl; and R₉ is OH, C₁₋₄alkoxy or -OC(=O)C₁₋₄alkyl; then one or more of the following groups do not occur simultaneously as defined:

(i) — R_4 is hydrogen; R_{10} and R_8 are independently OH, C_{1-4} alkoxy or $-OC(=O)C_{1-4}$ alkyl; and Y-Z is $-CH_2CH_2-$ or $-CH=CH-$;


(ii) — R_4 and R_8 are each hydrogen; R_{10} is OH, C_{1-4} alkoxy or $-OC(=O)C_{1-4}$ alkyl;

and Y-Z is $-CHR^X-CHR^Z-$, $-CH=CH-$ or ; wherein R^X and R^Z are independently hydrogen, C_{1-4} alkyl or C_{1-4} alkanoyl; and

(iii) — R_4 and R_{10} are each hydrogen, OH, C_{1-4} alkoxy or $-OC(=O)C_{1-4}$ alkyl; R_8 is hydrogen, OH, halogen, C_{1-4} alkoxy or $-OC(=O)C_{1-4}$ alkyl; and Y-Z is $-CH_2CH_2-$, $-CH=CH-$ or $-C(=O)CH_2-$.

2. (canceled)

3. (currently amended) The A compound of claim 1, the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein: R_1 is hydrogen, straight or branched C_{1-6} alkyl, straight or branched C_{1-6} heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R_2 and R_3 are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C_{1-6} alkyl, straight or branched C_{1-6} heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or

R_1 and R_2 , when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or

R_1 and R_3 , when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;

R₄ is hydrogen or halogen;

R₅ is hydrogen or a protecting group;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R₇, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R₉ is ~~hydrogen, halogen, hydroxyl, protected hydroxyl, OR₁₃, SR₁₃, NR₁₂R₁₃~~

~~X₁(CH₂)_pX₂-R₁₄, or is C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or -X₁(CH₂)_pX₂-R₁₄;~~

wherein R₁₂ and R₁₃ are, independently for each occurrence, hydrogen, C₁₋₆alkyl, aryl, heteroaryl, alkylaryl, ~~or alkylheteroaryl,~~ or a protecting group, ~~or R₁₂ and R₁₃ taken together may form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms,~~ and each of R₁₂ and R₁₃ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen, wherein X₁ and X₂ are each independently absent, or are oxygen, NH, or -N(alkyl), or wherein X₁-R₁₄ together are N₃, or are a saturated or unsaturated heterocyclic moiety,

p is 2-10, and

R₁₄ is hydrogen, or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is -(C=O)NHR₁₄₅, -(C=O)OR₁₄₅, or -(C=O)R₁₄₅, wherein each occurrence of R₁₄₅ is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl; or R₁₄ is -SO₂(R₁₄₆), wherein R₁₄₆ is an alkyl moiety, wherein one or more of R₁₄, R₁₄₅, or R₁₄₆ are optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen; or

R₈ and R₉ may, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;


R₁₀ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;

R_{11} is hydrogen, hydroxyl or protected hydroxyl;

X is absent or is O, NH, N-alkyl, CH_2 or S;


Y is CHR_{17} , O, $C=O$, CR_{17} or NR_{17} ; and Z is CHR_{18} , O, $C=O$, CR_{18} or NR_{18} , wherein each occurrence of R_{17} and R_{18} is independently hydrogen or C_{1-6} alkyl, or R_{17} and R_{18} taken together is $-O-$, $-CH_2-$ or $-NR_{19}-$, wherein R_{19} is hydrogen or C_{1-6} alkyl, and Y and Z may be connected by a single or double bond.

4. (original) The compound of claim 3, where X is oxygen and n is 1.
5. (original) The compound of claim 3, where R_4 is halogen.
6. (original) The compound of claim 3, where R_4 is fluorine.
7. (original) The compound of claim 3, where Y and Z together represent $-CH=CH-$.
8. (original) The compound of claim 3, where Y and Z together represent trans $-CH=CH-$.
9. (original) The compound of claim 3, wherein R_1 and R_2 are each methyl and R_3 is hydrogen and the compound has the structure:



wherein R_4 - R_{11} , n, X, Y and Z are as defined in claim 3.


10. (original) The compound of claim 9, wherein X is oxygen and n is 1.
11. (original) The compound of claim 9, wherein R_4 is halogen.
12. (original) The compound of claim 9, wherein Y and Z together represent $-CH=CH-$.
13. (original) The compound of claim 9, wherein X is oxygen, n is 1, R_4 is halogen and Y and Z together represent $-CH=CH-$.
14. (original) The compound of claim 12 or 13 wherein $-CH=CH-$ is trans.
15. (original) The compound of claim 3, wherein R_9 is $NR_{12}R_{13}$ and the compound has the structure:





wherein R_1 - R_{12} , n , X , Y and Z are as defined in claim 3, or

R_{13} and R_8 may, when taken together, form a cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydrogen, alkoxy, amino, alkylamino, aminoalkyl, and halogen.

16. (original) The compound of claim 15, wherein X is oxygen and n is 1.
17. (original) The compound of claim 15, wherein R_4 is halogen.
18. (original) The compound of claim 15, wherein Y and Z together represent $-\text{CH}=\text{CH}-$.
19. (original) The compound of claim 15, wherein R_1 and R_2 are each methyl and R_3 is hydrogen.
20. (original) The compound of claim 15, wherein X is oxygen, n is 1, R_1 and R_2 are each methyl, R_3 is hydrogen, R_4 is halogen, and Y and Z together represent $-\text{CH}=\text{CH}-$.
21. (original) The compound of claim 18 or 20, wherein $-\text{CH}=\text{CH}-$ is trans.
22. (currently amended) The compound of claim 1 having the structure:









or pharmaceutically acceptable salt, ester or salt of ester thereof.

23-36. (canceled)

37. (currently amended) A pharmaceutical composition comprising:
a compound of any one of claims 1, 3, 9 and 15; or pharmaceutically acceptable salt, ester or salt of ester thereof; and a pharmaceutically acceptable carrier.
38. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to inhibit NF- κ B activation.
39. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to inhibit AP-1 activation.
40. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to inhibit a protein kinase.
41. (previously presented) The pharmaceutical composition of claim 40, wherein the protein kinase is MEKK1, MEK1, VEGFr or PDGFr.
42. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to inhibit proliferation of cancerous cells and angiogenesis on solid tumors.
43. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to have an anti-inflammatory effect.

44. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to treat psoriasis.
45. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to reduce skin photodamage.
46. (original) The pharmaceutical composition of claim 37, wherein the compound is present in an amount effective to prevent restenosis.
- 47-65. (canceled)
66. (currently amended) The pharmaceutical composition of claim 37 wherein the compound has the structure:






or pharmaceutically acceptable salt, ester or salt of ester thereof.

67-80. (canceled)

81. (currently amended) A topical pharmaceutical composition for preventing or treating UVB-induced photodamage comprising:

a compound ~~of having~~ the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein R₁ is hydrogen, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R₂ and R₃ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or

R₁ and R₂, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or

R₁ and R₃, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;

R₄ is hydrogen or halogen;

R₅ is hydrogen, ~~or an oxygen protecting group or a prodrug moiety~~;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R₇, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R_9 is hydrogen, halogen, hydroxyl, protected hydroxyl, or $-SR_{12}NR_{13}R_{137}$
 $-X_1(CH_2)_pX_2R_{14}$, or is C_{1-6} alkyl optionally substituted with hydroxyl, protected
hydroxyl, halogen, amino, protected amino, or $-X_1(CH_2)_pX_2R_{14}$

wherein R_{12} and R_{13} are, independently for each occurrence, hydrogen, C_{1-6} alkyl,
aryl, heteroaryl, alkylaryl, or alkylheteroaryl, or a protecting group, or R_{12} and R_{13} ,
taken together may form a saturated or unsaturated cyclic ring containing 1 to 4
carbon atoms and 1 to 3 nitrogen or oxygen atoms, and each of R_{12} and R_{13} are
optionally further substituted with one or more occurrences of hydroxyl, protected
hydroxyl, alkoxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,
wherein X_1 and X_2 are each independently absent, or are oxygen, NH, or
 $-N(alkyl)$, or wherein X_2R_{14} together are N_3 , or are a saturated or unsaturated
heterocyclic moiety,

p is 2-10, and

R_{14} is hydrogen, or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is
 $-(C=O)NHR_{15}$, $-(C=O)OR_{15}$, or $-(C=O)R_{15}$, wherein each occurrence of R_{15} is
independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or
alkylheteroaryl; or R_{14} is $-SO_2(R_{16})$, wherein R_{16} is an alkyl moiety, wherein one or
more of R_{14} , R_{15} , or R_{16} are optionally substituted with one or more occurrences of
hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, alkylamino,
aminoalkyl, or halogen; or

R_8 and R_9 may, when taken together, form a saturated or unsaturated cyclic ring
containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally
substituted with hydroxyl, protected hydroxyl, alkoxy, amino, protected amino,
alkylamino, aminoalkyl, or halogen;

R_{10} is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;


R_{11} is hydrogen, hydroxyl or protected hydroxyl;


X is absent or is O, NH, N-alkyl, CH_2 or S;


Y is CHR_{17} , O, $C=O$, CR_{17} or NR_{17} ; and Z is CHR_{18} , O, $C=O$, CR_{18} or NR_{18} , wherein
each occurrence of R_{17} and R_{18} is independently hydrogen or C_{1-6} alkyl, or R_{17} and R_{18}
taken together is $-O-$, $-CH_2-$ or $-NR_{19}-$, wherein R_{19} is hydrogen or C_{1-6} alkyl, and Y and Z
may be connected by a single or double bond; and
a pharmaceutically acceptable carrier;

wherein the compound is present in an amount effective to prevent or treat UVB-induced photodamage.

82. (original) The pharmaceutical composition of claim 81, further comprising a cosmetic ingredient.
83. (original) The pharmaceutical composition of claim 82, wherein the cosmetic ingredient is a sunscreen.
84. (currently amended) A method for treating an inflammatory and/or autoimmune disorder or a disorder resulting from increased angiogenesis and/or cell proliferation comprising:
administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1, 3, 9 and 15; and a pharmaceutically acceptable carrier or diluent.
85. (original) The method of claim 84, wherein the method is for treating a disorder selected from the group consisting of rheumatoid arthritis, psoriasis, asthma, cancer, sepsis, inflammatory bowel disease, atopic dermatitis, Crohn's disease, and autoimmune disorders.
86. (original) The method of claim 84, wherein the method is for treating rheumatoid arthritis.
87. (original) The method of claim 84, wherein the method is for treating psoriasis.
88. (original) The method of claim 84, wherein the method is for treating asthma.
- 89-107. (canceled)
108. (currently amended) The method of claim 84, wherein the compound has the structure:








or pharmaceutically acceptable salt, ester or salt of ester thereof.

109-118. (canceled)

119. (currently amended) A method for providing protection against UVB-induced photodamage to a subject, said method comprising:
administering to the subject in need thereof a composition comprising a compound of having the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein R₁ is hydrogen, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R₂ and R₃ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or

R₁ and R₂, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or

R₁ and R₃, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;

R₄ is hydrogen or halogen;

R₅ is hydrogen, ~~or an oxygen protecting group or a prodrug moiety~~;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R₇, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkoxy, or C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R₉ is ~~hydrogen, halogen, hydroxyl, protected hydroxyl, OR₁₄₅, SR₁₄₅, NR₁₂R₁₃, X₄(CH₂)_pX₂-R₁₄, or is C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or X₄(CH₂)_pX₂-R₁₄~~;

wherein R₁₂ and R₁₃ are, independently for each occurrence, hydrogen, C₁₋₆alkyl, aryl, ~~heteroaryl~~, alkylaryl, ~~or alkylheteroaryl~~, or a protecting group, ~~or R₁₂ and R₁₃ taken together may form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms~~, and each of R₁₂ and R₁₃ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, alkylamino, aminoalkyl, or halogen, wherein X₄ and X₂ are each independently absent, or are oxygen, NH, or N(alkyl), or wherein X₂-R₁₄ together are N₃, or are a saturated or unsaturated heterocyclic moiety,

p is 2-10, and

R₁₄ is hydrogen, or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is ~~-(C=O)NHR₁₅, -(C=O)OR₁₅, or -(C=O)R₁₅~~, wherein each occurrence of R₁₅ is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl; or R₁₄ is -SO₂(R₁₆), wherein R₁₆ is an alkyl moiety, wherein one or more of R₁₄, R₁₅, or R₁₆ are optionally substituted with one or more occurrences of

~~hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen; or~~

R₈ and R₉ may, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;


R₁₀ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;

R₁₁ is hydrogen, hydroxyl or protected hydroxyl;

X is absent or is O, NH, N-alkyl, CH₂ or S;

Y is CHR₁₇, O, C=O, CR₁₇ or NR₁₇; and Z is CHR₁₈, O, C=O, CR₁₈ or NR₁₈, wherein each occurrence of R₁₇ and R₁₈ is independently hydrogen or C₁₋₆alkyl, or R₁₇ and R₁₈ taken together is -O-, -CH₂- or -NR₁₉-, wherein R₁₉ is hydrogen or C₁₋₆alkyl, and Y and Z may be connected by a single or double bond; and a pharmaceutically acceptable carrier or diluent.

120. (original) The method of claim 119, wherein in the step of administering, the composition is administered topically.
121. (original) The method of claim 119, wherein the photodamage is skin wrinkles.
122. (original) The method of claim 119, wherein the photodamage is a skin cancer.
123. (currently amended) A method for preventing or reducing the rate of restenosis, comprising:
inserting a stent into an obstructed blood vessel, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of having the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;
 wherein R₁ is hydrogen, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;
 R₂ and R₃ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or
 R₁ and R₂, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or
 R₁ and R₃, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;
 R₄ is hydrogen or halogen;

R₅ is hydrogen, ~~or an oxygen protecting group or a prodrug moiety~~;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R₇, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R₉ is ~~hydrogen, halogen, hydroxyl, protected hydroxyl, OR₁₂, SR₁₂, NR₁₂R₁₃~~

~~-X₁(CH₂)_pX₂-R₁₄, or is C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected-amino, or -X₁(CH₂)_pX₂-R₁₄;~~

wherein R₁₂ and R₁₃ are, independently for each occurrence, hydrogen, C₁₋₆alkyl, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, or a protecting group, ~~or R₁₂ and R₁₃ taken together may form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms, and each of R₁₂ and R₁₃ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen, wherein X₁ and X₂ are each independently absent, or are oxygen, NH, or -N(alkyl), or wherein X₂-R₁₄ together are N₃ or are a saturated or unsaturated heterocyclic moiety;~~

p is 2-10, and

R_{14} is hydrogen, or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is $-(C=O)NHR_{15}$, $-(C=O)OR_{15}$, or $-(C=O)R_{15}$, wherein each occurrence of R_{15} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl; or R_{14} is $-SO_2(R_{16})$, wherein R_{16} is an alkyl moiety, wherein one or more of R_{14} , R_{15} , or R_{16} are optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, alkylamino, aminoalkyl, or halogen; or

R_8 and R_9 may, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;

R_{10} is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;


R_{11} is hydrogen, hydroxyl or protected hydroxyl;

X is absent or is O, NH, N-alkyl, CH_2 or S;

Y is CHR_{17} , O, $C=O$, CR_{17} or NR_{17} ; and Z is CHR_{18} , O, $C=O$, CR_{18} or NR_{18} , wherein each occurrence of R_{17} and R_{18} is independently hydrogen or C_{1-6} alkyl, or R_{17} and R_{18} taken together is $-O-$, $-CH_2-$ or $-NR_{19}-$, wherein R_{19} is hydrogen or C_{1-6} alkyl, and Y and Z may be connected by a single or double bond; and optionally a pharmaceutically acceptable carrier or diluent;


such that the obstruction is eliminated and the composition is delivered in amounts effective to prevent or reduce the rate of restenosis;

with the proviso that the following groups do not occur simultaneously as defined: n is 1; X is O; R_1 is methyl; R_2 , R_3 , R_4 , R_5 , R_6 and R_{11} are each hydrogen; R_5 is hydrogen, C_{1-4} alkyl or $-(C=O)C_{1-4}$ alkyl; R_6 is hydrogen, OH, C_{1-4} alkoxy or $-OC(=O)C_{1-4}$ alkyl; R_9 and R_{10} are independently OH, C_{1-4} alkoxy or

$-OC(=O)C_{1-4}$ alkyl; and Y-Z is $-CHR^YCHR^Z-$, $-CH=CH-$ or ; wherein R^Y and R^Z are independently hydrogen, C_{1-4} alkyl or C_{1-4} alkanoyl.

124. (currently amended) A method for expanding the lumen of a body passageway, comprising:

inserting a stent into the passageway, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of ~~having~~ the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;
 wherein R₁ is hydrogen, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R₂ and R₃ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or

R₁ and R₂, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or

R₁ and R₃, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;

R₄ is hydrogen or halogen;

R₅ is hydrogen or a protecting group;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R₇, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R_9 is hydrogen, halogen, hydroxyl, protected hydroxyl, or $-SR_{12}NR_{13}X_1(CH_2)_pX_2R_{14}$, or is C_{1-6} alkyl optionally substituted with hydroxyl, protected hydroxyl, halogen, amino, protected amino, or $-X_1(CH_2)_pX_2R_{14}$;

wherein R_{12} and R_{13} are, independently for each occurrence, hydrogen, C_{1-6} alkyl, aryl, heteroaryl, alkylaryl, or alkylheteroaryl, or a protecting group, or R_{12} and R_{13} , taken together may form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms, and each of R_{12} and R_{13} are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, alkylamino, aminoalkyl, or halogen, wherein X_1 and X_2 are each independently absent, or are oxygen, NH, or $-N(alkyl)$, or wherein X_2R_{14} together are N_3 , or are a saturated or unsaturated heterocyclic moiety, p is 2-10, and

R_{14} is hydrogen, or an aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, or is $-(C=O)NHR_{15}$, $-(C=O)OR_{15}$, or $-(C=O)R_{15}$, wherein each occurrence of R_{15} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl; or R_{14} is $-SO_2(R_{16})$, wherein R_{16} is an alkyl moiety, wherein one or more of R_{14} , R_{15} , or R_{16} are optionally substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, alkylamino, aminoalkyl, or halogen; or

R_8 and R_9 may, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl, protected hydroxyl, alkoxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;

R_{10} is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;


R_{11} is hydrogen, hydroxyl or protected hydroxyl;

X is absent or is O, NH, N-alkyl, CH_2 or S;

Y is CHR_{17} , O, $C=O$, CR_{17} or NR_{17} ; and Z is CHR_{18} , O, $C=O$, CR_{18} or NR_{18} , wherein each occurrence of R_{17} and R_{18} is independently hydrogen or C_{1-6} alkyl, or R_{17} and R_{18} taken together is $-O-$, $-CH_2-$ or $-NR_{19}-$, wherein R_{19} is hydrogen or C_{1-6} alkyl, and Y and Z may be connected by a single or double bond; and optionally a pharmaceutically acceptable carrier or diluent;

such that the passageway is expanded.

125. (original) The method of claim 124, wherein the lumen of a body passageway is expanded in order to eliminate a biliary, gastrointestinal, esophageal, tracheal/bronchial, urethral and/or vascular obstruction.
126. (original) The method of claim 125, wherein the lumen of a body passageway is expanded in order to eliminate a vascular obstruction.
127. (new) A compound of the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;
 wherein R₁ is hydrogen, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R₂ and R₃ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or

R₁ and R₂, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or

R₁ and R₃, when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;

R₅ is hydrogen or a protecting group;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R₇, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;


R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R₁₂ and R₁₃ are, independently for each occurrence, hydrogen, C₁₋₆alkyl, aryl, alkylaryl, or a protecting group, and each of R₁₂ and R₁₃ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen; and

R₁₀ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino.

128. (new) A compound of claim 127, wherein R₁₂ is methyl, ethyl, propyl, isopropyl or butyl, optionally substituted with one or more occurrences of hydroxyl or protected hydroxyl and wherein R₁₃ is hydrogen or C₁₋₆alkyl.

129. (new) A compound of the formula:



or a pharmaceutically acceptable salt, ester or salt of ester thereof;